By Fineline Cube China-based Kexing Pharmaceutical (SHA: 688136) announced that a clinical trial application for SHEN26, an oral small-molecule COVID-19 drug co-developed with Shenzhen Antaiwei Biopharmaceutical Co., Ltd, has been accepted for review by the National Medical Products Administration (NMPA). SHEN26 is a novel coronavirus polymerase (RdRp) inhibitor designed to exert antiviral effects by inhibiting viral nucleic acid synthesis.
Pre-clinical Findings
Pre-clinical in vitro and in vivo studies demonstrated that SHEN26 can produce significant anti-SARS-CoV-2 effects. The drug exhibits substantial inhibitory activity against 2019-nCoV and its variants, with antiviral activity observed against both the original strain and known variant strains. SHEN26 has a clear mechanism of action, good oral bioavailability, and favorable safety profiles in repeated-dose animal studies. Importantly, it presents no risk of mutagenesis and no off-target effects.
National Recognition
SHEN26 is included in the national public security risk prevention and control and emergency technical equipment special program, underscoring its significance in China’s pandemic response strategy.-Fineline Info & Tech